Post-pandemic SARS-CoV-2 infection incidence: a Dutch prospective seroepidemiological cohort study
Abstract
After the acute phase of the COVID-19 pandemic, surveillance was reduced and serological monitoring became crucial to monitor SARS-CoV-2 infections. We estimated infection incidence in the Netherlands during 2023–2024 using repeated serological sampling. We used data from randomly-selected Dutch citizens aged 2-92 years that participated in the nationwide seroepidemiological PIENTER-Corona cohort study. Blood samples were collected thirteen times since April 2020 including four times in the period April 2023–October 2024 and tested for IgG antibodies against Spike-S1 (S1) and Nucleoprotein (N). Infections were identified through anti-N and/or anti-S1 (if not vaccinated) seroconversion or ≥ 4-fold increase, and self-reported positive tests. We estimated the weighted infection incidence (≥1) in 2023–2024 (N = 4261) and total infection count by October 2024 (N = 4574) in the Dutch population, overall and stratified by age, sex, ethnicity, comorbidities and healthcare profession. Between April 2023 and October 2024, the weighted infection incidence was 59.1% [56.8–61.4]; 55.4% was infected once and 3.7% was infected twice or more. Higher infection rates were seen in 30-60 year-olds (ranging 63.3–68.5%), those without comorbidities (62.0%) and those not working in healthcare (62.9%). By October 2024, the median infection count since the start of the pandemic was two; 21.9% had experienced one infection, 50.0% had two and 24.3% had three or more infections. A significant proportion (∼60%) of the Dutch population was infected with SARS-CoV-2 at least once in this 1.5-year post-pandemic period, with incidence varying between sociodemographic groups. These results highlight the importance of serological data to monitor and establish infection incidence in the absence of large-scale testing policies. This information is vital for evaluating disease burden.
Key messages: • Approximately 60% of the Dutch population experienced at least one SARS-CoV-2 infection in a 1.5 year post-pandemic period between April 2023 and October 2024.
• When large-scale testing is unavailable, serological data are crucial for monitoring and establishing infection incidence, and provide essential information for evaluating disease burden.
Related
- Incidence of and household responses to paediatric diarrhoeal disease and acute respiratory infection in Chitwan, Nepal: protocol for a prospective cohort study
- High Mortality in Adults With Community-Acquired Pneumonia Admitted to Hospitals in South Africa Before and During the COVID-19 Pandemic, Stratified by HIV Serostatus and Viral Load: Data From a Prospective Cohort Study (2019–2021)
- Prevalence and incidence of myopia among children and adolescents aged 6–19 years: a prospective cohort study
- Life’s Essential 8 moderates the association between Occupational Hazard Index and the incidence of hypertension among steelworkers: a prospective cohort study
- A systematic review and dose-response meta-analysis of prospective cohort studies on body mass index and leukemia incidence and mortality
BibTeX
@article{hagen2026postpandemic,
title = {{Post-pandemic SARS-CoV-2 infection incidence: a Dutch prospective seroepidemiological cohort study}},
author = {CCE Van Hagen and ERA Vos and HE De Melker and D Wong and G Den Hartog and FRM Van der Klis and S Van den Hof and MJ Knol},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.517},
url = {https://doi.org/10.1093/eurpub/ckag169.517},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Post-pandemic SARS-CoV-2 infection incidence: a Dutch prospective seroepidemiological cohort study
AU - CCE Van Hagen
AU - ERA Vos
AU - HE De Melker
AU - D Wong
AU - G Den Hartog
AU - FRM Van der Klis
AU - S Van den Hof
AU - MJ Knol
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.517
UR - https://doi.org/10.1093/eurpub/ckag169.517
AB - After the acute phase of the COVID-19 pandemic, surveillance was reduced and serological monitoring became crucial to monitor SARS-CoV-2 infections. We estimated infection incidence in the Netherlands during 2023–2024 using repeated serological sampling. We used data from randomly-selected Dutch citizens aged 2-92 years that participated in the nationwide seroepidemiological PIENTER-Corona cohort study. Blood samples were collected thirteen times since April 2020 including four times in the period April 2023–October 2024 and tested for IgG antibodies against Spike-S1 (S1) and Nucleoprotein (N). Infections were identified through anti-N and/or anti-S1 (if not vaccinated) seroconversion or ≥ 4-fold increase, and self-reported positive tests. We estimated the weighted infection incidence (≥1) in 2023–2024 (N = 4261) and total infection count by October 2024 (N = 4574) in the Dutch population, overall and stratified by age, sex, ethnicity, comorbidities and healthcare profession. Between April 2023 and October 2024, the weighted infection incidence was 59.1% [56.8–61.4]; 55.4% was infected once and 3.7% was infected twice or more. Higher infection rates were seen in 30-60 year-olds (ranging 63.3–68.5%), those without comorbidities (62.0%) and those not working in healthcare (62.9%). By October 2024, the median infection count since the start of the pandemic was two; 21.9% had experienced one infection, 50.0% had two and 24.3% had three or more infections. A significant proportion (∼60%) of the Dutch population was infected with SARS-CoV-2 at least once in this 1.5-year post-pandemic period, with incidence varying between sociodemographic groups. These results highlight the importance of serological data to monitor and establish infection incidence in the absence of large-scale testing policies. This information is vital for evaluating disease burden. Key messages: • Approximately 60% of the Dutch population experienced at least one SARS-CoV-2 infection in a 1.5 year post-pandemic period between April 2023 and October 2024. • When large-scale testing is unavailable, serological data are crucial for monitoring and establishing infection incidence, and provide essential information for evaluating disease burden.
SN - 1101-1262
SN - 1464-360X
ER -